{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:35:09Z","timestamp":1790476509406,"version":"4.1.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Major depressive disorder (MDD) is associated with altered mineralocorticoid receptor (MR) and glucocorticoid receptor function, and disturbed glutamatergic signaling. Both systems are closely intertwined and likely contribute not only to the pathophysiology of MDD, but also to the increased cardiovascular risk in MDD patients. Less is known about other steroid hormones, such as aldosterone and DHEA-S, and how they affect the glutamatergic system and cardiovascular disease risk in MDD. We examined salivary cortisol, aldosterone, and DHEA-S secretion after stimulation of MR and glutamatergic NMDA receptors in 116 unmedicated depressed patients, and 116 age- and sex-matched healthy controls. Patients (mean age\u2009=\u200934.7 years, SD\u2009=\u2009\u00b113.3; 78% women) and controls were randomized to four conditions: (a) control condition (placebo), (b) MR stimulation (0.4\u2009mg fludrocortisone), (c) NMDA stimulation (250\u2009mg D-cycloserine (DCS)), and (d) combined MR\/NMDA stimulation (fludrocortisone\u2009+\u2009DCS). We additionally determined the cardiovascular risk profile in both groups. DCS had no effect on steroid hormone secretion, while cortisol secretion decreased in both fludrocortisone conditions across groups. Independent of condition, MDD patients showed (1) increased cortisol, increased aldosterone, and decreased DHEA-S concentrations, and (2) increased glucose levels and decreased high-density lipoprotein cholesterol levels compared with controls. Depressed patients show profound alterations in several steroid hormone systems that are associated both with MDD pathophysiology and increased cardiovascular risk. Prospective studies should examine whether modulating steroid hormone levels might reduce psychopathology and cardiovascular risk in depressed patients.<\/jats:p>","DOI":"10.1038\/s41398-020-0789-7","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T17:02:41Z","timestamp":1587402161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression"],"prefix":"10.1038","volume":"10","author":[{"given":"Jan","family":"Nowacki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7457-0370","authenticated-orcid":false,"given":"Katja","family":"Wingenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kaczmarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Ri","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Salchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikram","family":"Abu-Tir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Piber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Hellmann-Regen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-997X","authenticated-orcid":false,"given":"Christian","family":"Otte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"789_CR1","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","volume":"2","author":"C Otte","year":"2016","unstructured":"Otte, C. et al. Major depressive disorder. Nat. Rev. Dis. Prim. 2, 16065 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"789_CR2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(07)61305-1","volume":"370","author":"DJ Brotman","year":"2007","unstructured":"Brotman, D. J., Golden, S. H. & Wittstein, I. S. The cardiovascular toll of stress. Lancet 370, 1089\u20131100 (2007).","journal-title":"Lancet"},{"key":"789_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn3138","volume":"13","author":"M Popoli","year":"2012","unstructured":"Popoli, M., Yan, Z., McEwen, B. S. & Sanacora, G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13, 22 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"789_CR4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/mp.2014.5","volume":"19","author":"G Treccani","year":"2014","unstructured":"Treccani, G. et al. Stress and corticosterone increase the readily releasable pool of glutamate vesicles in synaptic terminals of prefrontal and frontal cortex. Mol. Psychiatry 19, 433 (2014).","journal-title":"Mol. Psychiatry"},{"key":"789_CR5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PSY.0b013e31820ad12b","volume":"73","author":"C Stetler","year":"2011","unstructured":"Stetler, C. & Miller, G. E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 73, 114\u2013126 (2011).","journal-title":"Psychosom. Med."},{"key":"789_CR6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough, J. W., Abdallah, C. G. & Mathew, S. J. Targeting glutamate signalling in depression: progress and prospects. Nat. Rev. Drug Discov. 16, 472\u2013486 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"789_CR7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neubiorev.2016.07.003","volume":"74","author":"BWJH Penninx","year":"2017","unstructured":"Penninx, B. W. J. H. Depression and cardiovascular disease: epidemiological evidence on their linking mechanisms. Neurosci. Biobehav. Rev. 74, 277\u2013286 (2017).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"789_CR8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrcardio.2012.91","volume":"9","author":"CB Nemeroff","year":"2012","unstructured":"Nemeroff, C. B. & Goldschmidt-Clermont, P. J. Heartache and heartbreak\u2014the link between depression and cardiovascular disease. Nat. Rev. Cardiol. 9, 526 (2012).","journal-title":"Nat. Rev. Cardiol."},{"key":"789_CR9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrcardio.2016.181","volume":"14","author":"RM Carney","year":"2016","unstructured":"Carney, R. M. & Freedland, K. E. Depression and coronary heart disease. Nat. Rev. Cardiol. 14, 145 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"789_CR10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.psyneuen.2014.10.022","volume":"52","author":"F ter Heegde","year":"2015","unstructured":"ter Heegde, F., De Rijk, R. H. & Vinkers, C. H. The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 52, 92\u2013110 (2015).","journal-title":"Psychoneuroendocrinology"},{"key":"789_CR11","doi-asserted-by":"crossref","unstructured":"de Kloet, E., Meijer, O., de Nicola, A., de Rijk, R. & Jo\u00ebls, M. Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation. Front. Neuroendocrinol. 49, 124\u2013145 (2018).","DOI":"10.1016\/j.yfrne.2018.02.003"},{"key":"789_CR12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tins.2008.06.006","volume":"31","author":"CM Pariante","year":"2019","unstructured":"Pariante, C. M. & Lightman, S. L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 31, 464\u2013468 (2019).","journal-title":"Trends Neurosci."},{"key":"789_CR13","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1177\/0269881113499205","volume":"27","author":"MF Juruena","year":"2013","unstructured":"Juruena, M. F. et al. The role of mineralocorticoid receptor function in treatment-resistant depression. J. Psychopharmacol. 27, 1169\u20131179 (2013).","journal-title":"J. Psychopharmacol."},{"key":"789_CR14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.psyneuen.2012.05.006","volume":"38","author":"A Lembke","year":"2013","unstructured":"Lembke, A. et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary\u2013adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology 38, 115\u2013121 (2013).","journal-title":"Psychoneuroendocrinology"},{"key":"789_CR15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pnpbp.2016.08.003","volume":"71","author":"K Hinkelmann","year":"2016","unstructured":"Hinkelmann, K. et al. Mineralocorticoid receptor function in depressed patients and healthy individuals. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 71, 183\u2013188 (2016).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"789_CR16","doi-asserted-by":"crossref","unstructured":"Moriguchi, S. et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol. Psychiatry 24, 952\u2013964 (2019).","DOI":"10.1038\/s41380-018-0252-9"},{"key":"789_CR17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12031-016-0876-7","volume":"9","author":"SY Chan","year":"2017","unstructured":"Chan, S. Y., Matthews, E. & Burnet, P. W. ON or OFF?: modulating the N-methyl-D-aspartate receptor in major depression. Front. Mol. Neurosci. 9, 169 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"789_CR18","unstructured":"Food and Drug Administration. FDA Approves New Nasal Spray Medication for Treatment-resistant Depression; Available Only at a Certified Doctor\u2019s Office or Clinic. Retrieved June 11 (2019) from."},{"key":"789_CR19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S. & Duman, R. S. Ketamine: a paradigm shift for depression research and treatment. Neuron 101, 774\u2013778 (2019).","journal-title":"Neuron"},{"key":"789_CR20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/bja\/aev135","volume":"115","author":"N Khalili-Mahani","year":"2015","unstructured":"Khalili-Mahani, N., Martini, C. H., Olofsen, E., Dahan, A. & Niesters, M. Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion. Br. J. Anaesth. 115, 68\u201375 (2015).","journal-title":"Br. J. Anaesth."},{"key":"789_CR21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuroimage.2014.12.050","volume":"108","author":"N Khalili-Mahani","year":"2015","unstructured":"Khalili-Mahani, N. et al. Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men. NeuroImage 108, 396\u2013409 (2015).","journal-title":"NeuroImage"},{"key":"789_CR22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","volume":"16","author":"U Heresco-Levy","year":"2013","unstructured":"Heresco-Levy, U. et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 16, 501\u2013506 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"789_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyv102","volume":"19","author":"S Schade","year":"2016","unstructured":"Schade, S. & Paulus, W. D-Cycloserine in neuropsychiatric diseases: a systematic review. Int. J. Neuropsychopharmacol 19, 1\u20137 (2016).","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"789_CR24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1176\/appi.ajp.2016.16060735","volume":"173","author":"JT Kantrowitz","year":"2016","unstructured":"Kantrowitz, J. T., Milak, M. S., Mao, X., Shungu, D. C. & Mann, J. Jd-Cycloserine an NMDA glutamate receptor glycine site partial agonist, induces acute increases in brain glutamate plus glutamine and gaba comparable to ketamine. Am. J. Psychiatry 173, 1241\u20131242 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"789_CR25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev-clinpsy-050212-185526","volume":"9","author":"MA Whooley","year":"2013","unstructured":"Whooley, M. A. & Wong, J. M. Depression and cardiovascular disorders. Annu. Rev. Clin. Psychol. 9, 327\u2013354 (2013).","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"789_CR26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003755","volume":"5","author":"Y Zheng","year":"2016","unstructured":"Zheng, Y. et al. Metabolites of glutamate metabolism are associated with incident cardiovascular events in the PREDIMED PREvencion con DIeta MEDiterranea (PREDIMED) Trial. J. Am. Heart Assoc. 5, e003755 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"789_CR27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neubiorev.2009.07.005","volume":"34","author":"LD Kubzansky","year":"2010","unstructured":"Kubzansky, L. D. & Adler, G. K. Aldosterone: A forgotten mediator of the relationship between psychological stress and heart disease. Neurosci. Biobehav. Rev. 34, 80\u201386 (2010).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"789_CR28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2018.0850","volume":"178","author":"K Dahal","year":"2018","unstructured":"Dahal, K. et al. Aldosterone antagonist therapy and mortality in patients with ST-segment elevation myocardial infarction without heart failure: a systematic review and meta-analysis. JAMA Intern. Med. 178, 913\u2013920 (2018).","journal-title":"JAMA Intern. Med."},{"key":"789_CR29","volume":"6","author":"TT Wu","year":"2017","unstructured":"Wu, T. T. et al. Prognostic value of dehydroepiandrosterone sulfate for patients with cardiovascular disease: a systematic review and meta\u2010analysis. J. Am. Heart Assoc. 6, e004896 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"789_CR30","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.arcmed.2005.03.046","volume":"36","author":"E Emanuele","year":"2005","unstructured":"Emanuele, E., Geroldi, D., Minoretti, P., Coen, E. & Politi, P. Increased plasma aldosterone in patients with clinical depression. Arch. Med. Res. 36, 544\u2013548 (2005).","journal-title":"Arch. Med. Res."},{"key":"789_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000368265","volume":"128","author":"H Murck","year":"2014","unstructured":"Murck, H., B\u00fcttner, M., Kircher, T. & Konrad, C. Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression. Nephron. Physiol. 128, 17\u201325 (2014).","journal-title":"Nephron. Physiol."},{"key":"789_CR32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.psyneuen.2011.06.007","volume":"37","author":"S H\u00e4fner","year":"2012","unstructured":"H\u00e4fner, S. et al. To live alone and to be depressed, an alarming combination for the renin\u2013angiotensin\u2013aldosterone-system (RAAS). Psychoneuroendocrinology 37, 230\u2013237 (2012).","journal-title":"Psychoneuroendocrinology"},{"key":"789_CR33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jad.2014.11.051","volume":"174","author":"Q Hu","year":"2015","unstructured":"Hu, Q. et al. Clinical significance of decreased protein expression of dehydroepiandrosterone sulfate in the development of depression: a meta-analysis. J. Affect. Disord. 174, 416\u2013423 (2015).","journal-title":"J. Affect. Disord."},{"key":"789_CR34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/HYPERTENSIONAHA.111.00797","volume":"61","author":"A Gabor","year":"2013","unstructured":"Gabor, A. & Leenen, F. H. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II\u2013induced hypertension. Hypertension 61, 1083\u20131090 (2013).","journal-title":"Hypertension"},{"key":"789_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2019.04.001","volume":"151","author":"E Zoupa","year":"2019","unstructured":"Zoupa, E., Gravanis, A. & Pitsikas, N. The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats. Neuropharmacology 151, 74\u201383 (2019).","journal-title":"Neuropharmacology"},{"key":"789_CR36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2018.03.023","volume":"1688","author":"M Zaric","year":"2018","unstructured":"Zaric, M. et al. Regional-specific effects of cerebral ischemia\/reperfusion and dehydroepiandrosterone on synaptic NMDAR\/PSD-95 complex in male Wistar rats. Brain Res. 1688, 73\u201380 (2018).","journal-title":"Brain Res."},{"key":"789_CR37","unstructured":"Association A. P. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae) (American Psychiatric Pub, 2013)."},{"key":"789_CR38","doi-asserted-by":"crossref","unstructured":"Hamilton M. The Hamilton rating scale for depression. Assessment of depression 143\u2013152 (Springer, 1986).","DOI":"10.1007\/978-3-642-70486-4_14"},{"key":"789_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck, A. T., Ward, C., Mendelson, M., Mock, J. & Erbaugh, J. Beck depression inventory (BDI). Arch. Gen. Psychiatry 4, 561\u2013571 (1961).","journal-title":"Arch. Gen. Psychiatry"},{"key":"789_CR40","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0024-3205(01)00996-1","volume":"68","author":"S Edwards","year":"2001","unstructured":"Edwards, S., Clow, A., Evans, P. & Hucklebridge, F. Exploration of the awakening cortisol response in relation to diurnal cortisol secretory activity. Life Sci. 68, 2093\u20132103 (2001).","journal-title":"Life Sci."},{"key":"789_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. methods"},{"key":"789_CR42","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00213-016-4380-0","volume":"233","author":"K Schultebraucks","year":"2016","unstructured":"Schultebraucks, K. et al. Selective attention to emotional cues and emotion recognition in healthy subjects: the role of mineralocorticoid receptor stimulation. Psychopharmacology 233, 3405\u20133415 (2016).","journal-title":"Psychopharmacology"},{"key":"789_CR43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.psyneuen.2005.02.010","volume":"30","author":"HM Burke","year":"2005","unstructured":"Burke, H. M., Davis, M. C., Otte, C. & Mohr, D. C. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 30, 846\u2013856 (2005).","journal-title":"Psychoneuroendocrinology"},{"key":"789_CR44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0893-133X(00)00194-9","volume":"24","author":"N Hergovich","year":"2001","unstructured":"Hergovich, N. et al. Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men: a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 24, 590 (2001).","journal-title":"Neuropsychopharmacology"},{"key":"789_CR45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199\u2013214 (1994).","journal-title":"Arch. Gen. Psychiatry"},{"key":"789_CR46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s002130050662","volume":"138","author":"BN van Berckel","year":"1998","unstructured":"van Berckel, B. N. et al. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology 138, 190\u2013197 (1998).","journal-title":"Psychopharmacology"},{"key":"789_CR47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0893-133X(96)00196-0","volume":"16","author":"BN van Berckel","year":"1997","unstructured":"van Berckel, B. N. et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 16, 317 (1997).","journal-title":"Neuropsychopharmacology"},{"key":"789_CR48","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/npp.2013.179","volume":"38","author":"GB Feld","year":"2013","unstructured":"Feld, G. B., Lange, T., Gais, S. & Born, J. Sleep-dependent declarative memory consolidation\u2014unaffected after blocking NMDA or AMPA receptors but enhanced by NMDA coagonist D-cycloserine. Neuropsychopharmacology 38, 2688 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"789_CR49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopsych.2015.09.007","volume":"80","author":"MW Otto","year":"2016","unstructured":"Otto, M. W. et al. Enhancement of psychosocial treatment with d-cycloserine: models, moderators, and future directions. Biol. Psychiatry 80, 274\u2013283 (2016).","journal-title":"Biol. Psychiatry"},{"key":"789_CR50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pnpbp.2019.02.001","volume":"92","author":"B Peyrovian","year":"2019","unstructured":"Peyrovian, B. et al. The glycine site of NMDA receptors: a target for cognitive enhancement in psychiatric disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 92, 387\u2013404 (2019).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"789_CR51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.psyneuen.2018.09.010","volume":"105","author":"K Wingenfeld","year":"2019","unstructured":"Wingenfeld, K. & Otte, C. Mineralocorticoid receptor function and cognition in health and disease. Psychoneuroendocrinology 105, 25\u201335 (2019).","journal-title":"Psychoneuroendocrinology"},{"key":"789_CR52","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12675","volume":"31","author":"ER de Kloet","year":"2019","unstructured":"de Kloet, E. R., de Kloet, S. F., de Kloet, C. S. & de Kloet, A. D. Top\u2010down and bottom\u2010up control of stress\u2010coping. J. Neuroendocrinol. 31, e12675 (2019).","journal-title":"J. Neuroendocrinol."},{"key":"789_CR53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/npp.2014.181","volume":"40","author":"C Otte","year":"2015","unstructured":"Otte, C. et al. Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals. Neuropsychopharmacology 40, 386\u2013393 (2015).","journal-title":"Neuropsychopharmacology"},{"key":"789_CR54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.euroneuro.2017.04.001","volume":"27","author":"CM Pariante","year":"2017","unstructured":"Pariante, C. M. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur. Neuropsychopharmacol. 27, 554\u2013559 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"789_CR55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yhbeh.2016.11.018","volume":"89","author":"HS Kamin","year":"2017","unstructured":"Kamin, H. S. & Kertes, D. A. Cortisol and DHEA in development and psychopathology. Hormones Behav. 89, 69\u201385 (2017).","journal-title":"Hormones Behav."},{"key":"789_CR56","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.psyneuen.2010.04.001","volume":"35","author":"U Knorr","year":"2010","unstructured":"Knorr, U., Vinberg, M., Kessing, L. V. & Wetterslev, J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 35, 1275\u20131286 (2010).","journal-title":"Psychoneuroendocrinology"},{"key":"789_CR57","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-3-15","volume":"3","author":"H Murck","year":"2003","unstructured":"Murck, H. et al. The renin-angiotensin-aldosterone system in patients with depression compared to controls\u2013a sleep endocrine study. BMC Psychiatry 3, 15 (2003).","journal-title":"BMC Psychiatry"},{"key":"789_CR58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpsychires.2017.04.011","volume":"91","author":"V Segeda","year":"2017","unstructured":"Segeda, V., Izakova, L., Hlavacova, N., Bednarova, A. & Jezova, D. Aldosterone concentrations in saliva reflect the duration and severity of depressive episode in a sex dependent manner. J. Psychiatr. Res. 91, 164\u2013168 (2017).","journal-title":"J. Psychiatr. Res."},{"key":"789_CR59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpsychires.2015.04.012","volume":"66","author":"M B\u00fcttner","year":"2015","unstructured":"B\u00fcttner, M. et al. Target-based biomarker selection\u2013mineralocorticoid receptor-related biomarkers and treatment outcome in major depression. J. Psychiatr. Res. 66, 24\u201337 (2015).","journal-title":"J. Psychiatr. Res."},{"key":"789_CR60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/YIC.0000000000000239","volume":"34","author":"H Murck","year":"2019","unstructured":"Murck, H., Braunisch, M. C., Konrad, C., Jezova, D. & Kircher, T. Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression. Int. Clin. Psychopharmacol. 34, 18\u201326 (2019).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"789_CR61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1055\/s-0043-121706","volume":"49","author":"MS Velema","year":"2017","unstructured":"Velema, M. S. et al. Health-related quality of life and mental health in primary aldosteronism: a systematic review. Horm. Metab. Res. 49, 943\u2013950 (2017).","journal-title":"Horm. Metab. Res."},{"key":"789_CR62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0032-1301921","volume":"44","author":"HE K\u00fcnzel","year":"2012","unstructured":"K\u00fcnzel, H. E. Psychopathological symptoms in patients with primary hyperaldosteronism \u2013 possible pathways. Horm. Metab. Res. 44, 202\u2013207 (2012).","journal-title":"Horm. Metab. Res."},{"key":"789_CR63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jpsychires.2011.10.003","volume":"46","author":"M Franklin","year":"2012","unstructured":"Franklin, M., Bermudez, I., Murck, H., Singewald, N. & Gaburro, S. Sub-chronic dietary tryptophan depletion \u2013 an animal model of depression with improved face and good construct validity. J. Psychiatr. Res. 46, 239\u2013247 (2012).","journal-title":"J. Psychiatr. Res."},{"key":"789_CR64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S1461145711000368","volume":"15","author":"N Hlavacova","year":"2012","unstructured":"Hlavacova, N. et al. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int. J. Neuropsychopharmacol. 15, 247\u2013265 (2012).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"789_CR65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1192\/bjp.177.6.505","volume":"177","author":"T Harris","year":"2000","unstructured":"Harris, T. et al. Morning cortisol as a risk factor for subsequent major depressive disorder in adult women. Br. J. Psychiatry 177, 505\u2013510 (2000).","journal-title":"Br. J. Psychiatry"},{"key":"789_CR66","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1192\/bjp.177.6.499","volume":"177","author":"IM Goodyer","year":"2000","unstructured":"Goodyer, I. M., Herbert, J., Tamplin, A. & Altham, P. Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. Br. J. Psychiatry 177, 499\u2013504 (2000).","journal-title":"Br. J. Psychiatry"},{"key":"789_CR67","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000431152","volume":"102","author":"M Franklin","year":"2015","unstructured":"Franklin, M. et al. Aldosterone signals the onset of depressive behaviour in a female rat model of depression along with SSRI treatment resistance. Neuroendocrinology 102, 274\u2013287 (2015).","journal-title":"Neuroendocrinology"},{"key":"789_CR68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jad.2013.01.014","volume":"148","author":"AL Lopresti","year":"2013","unstructured":"Lopresti, A. L., Hood, S. D. & Drummond, P. D. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. J. Affect. Disord. 148, 12\u201327 (2013).","journal-title":"J. Affect. Disord."},{"key":"789_CR69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FJC.0000000000000329","volume":"67","author":"E Gomez-Sanchez","year":"2016","unstructured":"Gomez-Sanchez, E. Third generation mineralocorticoid receptor antagonists; why we need a fourth. J. Cardiovascular Pharmacol. 67, 26 (2016).","journal-title":"J. Cardiovascular Pharmacol."},{"key":"789_CR70","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","volume":"234","author":"JJ DuPont","year":"2017","unstructured":"DuPont, J. J. & Jaffe, I. Z. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: the role of the mineralocorticoid receptor in the vasculature. J. Endocrinol. 234, T67\u2013T82 (2017).","journal-title":"J. Endocrinol."},{"key":"789_CR71","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1210\/jc.2010-2137","volume":"96","author":"M Kumari","year":"2011","unstructured":"Kumari, M., Shipley, M., Stafford, M. & Kivimaki, M. Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study. J. Clin. Endocrinol. Metab. 96, 1478\u20131485 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"789_CR72","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1210\/jc.2010-0192","volume":"95","author":"N Vogelzangs","year":"2010","unstructured":"Vogelzangs, N. et al. Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. J. Clin. Endocrinol. Metab. 95, 4959\u20134964 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"789_CR73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.10.084","volume":"203","author":"F Hammer","year":"2016","unstructured":"Hammer, F. et al. High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. Int. J. Cardiol. 203, 69\u201373 (2016).","journal-title":"Int. J. Cardiol."},{"key":"789_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","volume":"65","author":"A Buglioni","year":"2015","unstructured":"Buglioni, A. et al. Circulating aldosterone and natriuretic peptides in the general community. Hypertension 65, 45\u201353 (2015).","journal-title":"Hypertension"},{"key":"789_CR75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archpsyc.62.2.154","volume":"62","author":"PJ Schmidt","year":"2005","unstructured":"Schmidt, P. J. et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch. Gen. Psychiatry 62, 154\u2013162 (2005).","journal-title":"Arch. Gen. Psychiatry"},{"key":"789_CR76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.18632\/aging.100327","volume":"3","author":"EP Weiss","year":"2011","unstructured":"Weiss, E. P., Villareal, D. T., Fontana, L., Han, D.-H. & Holloszy, J. O. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY) 3, 533 (2011).","journal-title":"Aging (Albany NY)"},{"key":"789_CR77","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard, B. G. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur. Heart J. 37, 1944\u20131958 (2016).","journal-title":"Eur. Heart J."},{"key":"789_CR78","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.jacc.2012.02.043","volume":"59","author":"M Benn","year":"2012","unstructured":"Benn, M. et al. Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J. Am. Coll. Cardiol. 59, 2356\u20132365 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"789_CR79","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ypmed.2012.09.013","volume":"55","author":"H Imano","year":"2012","unstructured":"Imano, H. et al. Non-fasting blood glucose and risk of incident coronary heart disease in middle-aged general population: The Circulatory Risk in Communities Study (CIRCS). Preventive Med. 55, 603\u2013607 (2012).","journal-title":"Preventive Med."},{"key":"789_CR80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530600569877","volume":"38","author":"SJ Webb","year":"2006","unstructured":"Webb, S. J., Geoghegan, T. E., Prough, R. A. & Michael Miller, K. K. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab. Rev. 38, 89\u2013116 (2006).","journal-title":"Drug Metab. Rev."},{"key":"789_CR81","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1210\/jcem.83.6.4876","volume":"83","author":"RH Straub","year":"1998","unstructured":"Straub, R. H. et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J. Clin. Endocrinol. Metab. 83, 2012\u20132017 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"789_CR82","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00003246-200105000-00012","volume":"29","author":"MM Folan","year":"2001","unstructured":"Folan, M. M. et al. Dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and cortisol concentrations in intensive care unit patients. Crit. Care Med. 29, 965\u2013970 (2001).","journal-title":"Crit. Care Med."},{"key":"789_CR83","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0006-291X(77)90242-X","volume":"78","author":"M Agarwal","year":"1977","unstructured":"Agarwal, M., Coupry, F. & Philippe, M. Physiological activity and receptor binding of 9\u03b1 fluorohydrocortisone. Biochem. Biophys. Res. Commun. 78, 747\u2013753 (1977).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"789_CR84","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/eje.0.1510397","volume":"151","author":"C Grossmann","year":"2004","unstructured":"Grossmann, C. et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur. J. Endocrinol. 151, 397\u2013406 (2004).","journal-title":"Eur. J. Endocrinol."},{"key":"789_CR85","unstructured":"Miller D. Adrenocorticoids. in Foye\u2019s Principles of Medicinal Chemistry, 6th edn, (eds Lemke, T. L. & Williams, D. A.) 890\u2013891 (Lippincott Williams & Wilkins, a Wolters Kluwer business: Baltimore, MD, 2008)."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-0789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-0789-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-0789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:34:02Z","timestamp":1670232842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-0789-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1038\/s41398-020-0789-7","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"8 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.O. has received honoraria for lectures and\/or scientific advice from Allergan, Ferring, Fortbildungskolleg, Limes Klinikgruppe, Lundbeck, MedOnline, Medical Tribune, Neuraxpharm, SAGE Therapeutics, and Stillachhaus. All other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"109"}}